Search

Your search keyword '"Bes, Marta"' showing total 27 results
Start Over Author "Bes, Marta" Search Limiters Full Text
27 results on '"Bes, Marta"'

2. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020

Author

Bes, Marta, Costafreda, Maria I., Riveiro-Barciela, Mar, Piron, Maria, Rico, Angie, Quer, Josep, Puig, Lluis, and Sauleda, Silvia

Subjects
Catalonia, Spain -- Health aspects, Hepatitis E -- Statistics -- Risk factors -- Diagnosis, Blood transfusion -- Statistics -- Complications and side effects, Blood donors -- Statistics, Medical screening -- Statistics, Health
Abstract

Hepatitis E virus (HEV; family Hepeviridae, genus Orthohepevirus) (1) is an RNA virus that causes acute viral hepatitis in humans. Five HEV genotypes are known to infect humans. Genotypes 1 [...]

Published
2022
Full Text
View/download PDF

3. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis

Author

Köhler, Bruno, primary, Bes, Marta, additional, Chan, Henry Lik-Yuen, additional, Esteban, Juan Ignacio, additional, Piratvisuth, Teerha, additional, Sukeepaisarnjaroen, Wattana, additional, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Mang, Anika, additional, Morgenstern, David, additional, Swiatek-de Lange, Magdalena, additional, and Dayyani, Farshid, additional

Published
2024
Full Text
View/download PDF

4. Discovery of a haptoglobin glycopeptides biomarker panel for early diagnosis of hepatocellular carcinoma

Author

Kohansal-Nodehi, Mahdokht, primary, Swiatek-de Lange, Magdalena, additional, Kroeniger, Konstantin, additional, Rolny, Vinzent, additional, Tabarés, Glòria, additional, Piratvisuth, Teerha, additional, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Sukeepaisarnjaroen, Wattana, additional, Esteban, Juan Ignacio, additional, Bes, Marta, additional, Köhler, Bruno, additional, Chan, Henry Lik-Yuen, additional, and Busskamp, Holger, additional

Published
2023
Full Text
View/download PDF

5. Comparison of Extracellular Vesicle Isolation Methods for miRNA Sequencing

Author

Llorens-Revull, Meritxell, primary, Martínez-González, Brenda, additional, Quer, Josep, additional, Esteban, Juan Ignacio, additional, Núñez-Moreno, Gonzalo, additional, Mínguez, Pablo, additional, Burgui, Idoia, additional, Ramos-Ruíz, Ricardo, additional, Soria, María Eugenia, additional, Rico, Angie, additional, Riveiro-Barciela, Mar, additional, Sauleda, Silvia, additional, Piron, María, additional, Corrales, Irene, additional, Borràs, Francesc E., additional, Rodríguez-Frías, Francisco, additional, Rando, Ariadna, additional, Ramírez-Serra, Clara, additional, Camós, Silvia, additional, Domingo, Esteban, additional, Bes, Marta, additional, Perales, Celia, additional, and Costafreda, Maria Isabel, additional

Published
2023
Full Text
View/download PDF

6. Comparison of Extracellular Vesicle Isolation Methods for miRNA Sequencing

Author

Instituto de Salud Carlos III, European Commission, Ministerio de Economía y Empresa (España), Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Fundació La Marató de TV3, Ministerio de Ciencia e Innovación (España), Comunidad de Madrid, CSIC - Plataforma Temática Interdisciplinar del CSIC Salud Global (PTI Salud Global), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Ramón Areces, Banco Santander, Llorens-Revull, Meritxell, Martínez-González, Brenda, Quer, Josep, Esteban, Juan Ignacio, Núñez-Moreno, Gonzalo, Mínguez, Pablo, Burgui, Idoia, Ramos-Ruiz, Ricardo, Soria, María Eugenia, Rico, Angie, Riveiro-Barciela, Mar, Sauleda, Silvia, Piron, María, Corrales, Irene, Borràs, Francesc E., Rodríguez-Frías, Francisco, Rando, Ariadna, Ramírez-Serra, Clara, Camós, Silvia, Domingo, Esteban, Bes, Marta, Perales, Celia, Costafreda, María Isabel, Instituto de Salud Carlos III, European Commission, Ministerio de Economía y Empresa (España), Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Fundació La Marató de TV3, Ministerio de Ciencia e Innovación (España), Comunidad de Madrid, CSIC - Plataforma Temática Interdisciplinar del CSIC Salud Global (PTI Salud Global), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), Fundación Ramón Areces, Banco Santander, Llorens-Revull, Meritxell, Martínez-González, Brenda, Quer, Josep, Esteban, Juan Ignacio, Núñez-Moreno, Gonzalo, Mínguez, Pablo, Burgui, Idoia, Ramos-Ruiz, Ricardo, Soria, María Eugenia, Rico, Angie, Riveiro-Barciela, Mar, Sauleda, Silvia, Piron, María, Corrales, Irene, Borràs, Francesc E., Rodríguez-Frías, Francisco, Rando, Ariadna, Ramírez-Serra, Clara, Camós, Silvia, Domingo, Esteban, Bes, Marta, Perales, Celia, and Costafreda, María Isabel

Abstract

MicroRNAs (miRNAs) encapsulated in extracellular vesicles (EVs) are potential diagnostic and prognostic biomarkers. However, discrepancies in miRNA patterns and their validation are still frequent due to differences in sample origin, EV isolation, and miRNA sequencing methods. The aim of the present study is to find a reliable EV isolation method for miRNA sequencing, adequate for clinical application. To this aim, two comparative studies were performed in parallel with the same human plasma sample: (i) isolation and characterization of EVs obtained using three procedures: size exclusion chromatography (SEC), iodixanol gradient (GRAD), and its combination (SEC+GRAD) and (ii) evaluation of the yield of miRNA sequences obtained using NextSeq 500 (Illumina) and three miRNA library preparation protocols: NEBNext, NEXTFlex, and SMARTer smRNA-seq. The conclusion of comparison (i) is that recovery of the largest amount of EVs and reproducibility were attained with SEC, but GRAD and SEC+GRAD yielded purer EV preparations. The conclusion of (ii) is that the NEBNext library showed the highest reproducibility in the number of miRNAs recovered and the highest diversity of miRNAs. These results render the combination of GRAD EV isolation and NEBNext library preparation for miRNA retrieval as adequate for clinical applications using plasma samples.

Published
2023

7. Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection

Author

Costafreda, Maria I., primary, Sauleda, Silvia, additional, Riveiro-Barciela, Mar, additional, Rico, Angie, additional, Llorens-Revull, Meritxell, additional, Guix, Susana, additional, Pintó, Rosa M., additional, Bosch, Albert, additional, Rodríguez-Frías, Francisco, additional, Rando, Ariadna, additional, Piron, Maria, additional, and Bes, Marta, additional

Published
2023
Full Text
View/download PDF

8. Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection

Author

Costafreda Salvany, Maria Isabel, Sauleda, Silvia, Riveiro Barciela, Mar, Rico, Angie, Llorens-Revull, Meritxell, Guix, Susana, Pintó, Rosa M., Bosch, Albert, Rodríguez Frías, Francisco, Rando-Segura, Ariadna, Piron, Maria, Bes, Marta, and Universitat Autònoma de Barcelona. Departament de Medicina

Subjects
Microbiology (medical), Micro RNAs, General Immunology and Microbiology, Ecology, Physiology, Cell Biology, Infection outcomes, Microrna, MicroRNAs, Infectious Diseases, Prognostic indicators, Genetics, Hepatitis E virus, RNA, Virus de l'hepatitis E, Diagnostics
Abstract

The pathogenic mechanisms determining the diverse clinical outcomes of HEV infection (e.g., self-limiting versus chronic or symptomatic versus asymptomatic) are not yet understood. Because specific microRNA signatures during viral infection inform the cellular processes involved in virus replication and pathogenesis, we investigated plasma microRNA profiles in 44 subjects, including patients with symptomatic acute (AHE, n = 7) and chronic (CHE, n = 6) hepatitis E, blood donors with asymptomatic infection (HEV BDs, n = 9), and anti-HEV IgG + IgM − (exposed BDs, n = 10) and anti-HEV IgG − IgM − (naive BDs, n = 12) healthy blood donors. By measuring the abundance of 179 microRNAs in AHE patients and naive BDs by reverse transcription-quantitative PCR (RT-qPCR), we identified 51 potential HEV-regulated microRNAs (P value adjusted for multiple testing by the Benjamini-Hochberg correction [ P ] < 0.05). Further analysis showed that HEV genotype 3 infection is associated with miR-122, miR-194, miR-885, and miR-30a upregulation and miR-221, miR-223, and miR-27a downregulation. AHE patients showed significantly higher levels of miR-122 and miR-194 and lower levels of miR-221, miR-27a, and miR-335 than HEV BDs. This specific microRNA signature in AHE could promote virus replication and reduce antiviral immune responses, contributing to the development of clinical symptoms. We found that miR-194, miR-335, and miR-221 can discriminate between asymptomatic HEV infections and those developing acute symptoms, whereas miR-335 correctly classifies AHE and CHE patients. Our data suggest that diverse outcomes of HEV infection result from different HEV-induced microRNA dysregulations. The specific microRNA signatures described offer novel information that may serve to develop biomarkers of HEV infection outcomes and improve our understanding of HEV pathogenesis, which may facilitate the identification of antiviral targets. IMPORTANCE There is increasing evidence that viruses dysregulate the expression and/or secretion of microRNAs to promote viral replication, immune evasion, and pathogenesis. In this study, we evaluated the change in microRNA abundance in patients with acute or chronic HEV infection and asymptomatic HEV-infected blood donors. Our results suggest that different HEV-induced microRNA dysregulations may contribute to the diverse clinical manifestations of HEV infection. The specific microRNA signatures identified in this study hold potential as predictive markers of HEV infection outcomes, which would improve the clinical management of hepatitis E patients, particularly of those developing severe symptoms or chronic infections. Furthermore, this study provides new insights into HEV pathogenesis that may serve to identify antiviral targets, which would have a major impact because no effective treatments are yet available

Published
2023

9. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience

Author

Piron, Maria, Salvador, Fernando, Caballero Requero, Estrella, Sánchez-Montalvá, Adrián, Bes, Marta, Casamitjana, Natàlia, Puig Sanz, Lluís, Molina Romero, Israel, Sauleda, Silvia, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Piron M, Bes M, Sauleda S] Banc de Sang i Teixits de Catalunya (Blood and Tissue Bank of Catalonia, BST), Transfusion Safety Laboratory, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Salvador F, Sánchez-Montalvá A, Molina I] Centre de Salut Internacional i Malalties Transmissibles Drassanes-Vall d'Hebron Hospital Universitari, Barcelona, Spain. Servei de Malalties Infecciones, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Caballero E] Laboratori de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Casamitjana N] Banc de Sang i Teixits de Catalunya (Blood and Tissue Bank of Catalonia, BST), Transfusion Safety Laboratory, Barcelona, Spain. [Puig L] Banc de Sang i Teixits de Catalunya (Blood and Tissue Bank of Catalonia, BST), Transfusion Safety Laboratory, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd), Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adult, Male, personas::donantes de tejidos::donantes de sangre [DENOMINACIONES DE GRUPOS], Blood Donors, Virus Diseases::RNA Virus Infections::Retroviridae Infections::Deltaretrovirus Infections [DISEASES], Deltaretrovirus, Virology, Humans, Malalties transmissibles, Infeccions per retrovirus, transfusion, Other subheadings::Other subheadings::/transmission [Other subheadings], Human T-lymphotropic virus 1, screening, virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Deltaretrovirus [ENFERMEDADES], Human T-lymphotropic virus 2, HTLV-I Infections, HTLV-1/2, blood donors, leukoreduction, Spain, Infectious Diseases, Persons::Tissue Donors::Blood Donors [NAMED GROUPS], HTLV-1, HTLV-II Infections, Otros calificadores::Otros calificadores::/transmisión [Otros calificadores], Female, Donants de sang
Abstract

Spain; Screening; Transfusion España; Cribado; Transfusión Espanya; Cribratge; Transfusió Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d’Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety. A.S.-M was supported by a postdoctoral grant “Juan Rodés” (JE18/00022) from the Instituto de Salud Carlos III through the Spanish Ministry of Economy and Competitiveness.

Published
2022

11. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma

Author

Malik, Juliane, primary, Klammer, Martin, additional, Rolny, Vinzent, additional, Chan, Henry Lik-Yuen, additional, Piratvisuth, Teerha, additional, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Sukeepaisarnjaroen, Wattana, additional, Esteban, Juan Ignacio, additional, Bes, Marta, additional, Köhler, Bruno, additional, and Swiatek-de Lange, Magdalena, additional

Published
2022
Full Text
View/download PDF

12. ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype

Author

Roade, Luisa, primary, Riveiro-Barciela, Mar, additional, Palom, Adriana, additional, Rodríguez-Frías, Francisco, additional, Bes, Marta, additional, Rando, Ariadna, additional, Salcedo, María Teresa, additional, Casillas, Rosario, additional, Vargas-Accarino, Elena, additional, Tabernero, David, additional, Sauleda, Silvia, additional, Esteban, Rafael, additional, and Buti, María, additional

Published
2022
Full Text
View/download PDF

13. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study

Author

Piratvisuth, Teerha, primary, Tanwandee, Tawesak, additional, Thongsawat, Satawat, additional, Sukeepaisarnjaroen, Wattana, additional, Esteban, Juan Ignacio, additional, Bes, Marta, additional, Köhler, Bruno, additional, He, Ying, additional, Swiatek‐de Lange, Magdalena, additional, Morgenstern, David, additional, and Chan, Henry Lik‐Yuen, additional

Published
2021
Full Text
View/download PDF

15. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

Author

Llorens-Revull, Meritxell, primary, Costafreda, Maria Isabel, additional, Rico, Angie, additional, Guerrero-Murillo, Mercedes, additional, Soria, Maria Eugenia, additional, Píriz-Ruzo, Sofía, additional, Vargas-Accarino, Elena, additional, Gabriel-Medina, Pablo, additional, Rodríguez-Frías, Francisco, additional, Riveiro-Barciela, Mar, additional, Perales, Celia, additional, Quer, Josep, additional, Sauleda, Silvia, additional, Esteban, Juan Ignacio, additional, and Bes, Marta, additional

Published
2021
Full Text
View/download PDF

16. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

Author

Llorens-Revull, Meritxell, Costafreda, Maria Isabel, Rico, Angie, Guerrero-Murillo, Mercedes, Soria, Maria Eugenia, Píriz-Ruzo, Sofía, Vargas-Accarino, Elena, Gabriel-Medina, Pablo, Rodríguez-Frías, Francisco, Riveiro-Barciela, Mar, Perales, Celia, Quer, Josep, Sauleda, Silvia, Esteban Mur, Juan Ignacio, Bes, Marta, Llorens-Revull, Meritxell, Costafreda, Maria Isabel, Rico, Angie, Guerrero-Murillo, Mercedes, Soria, Maria Eugenia, Píriz-Ruzo, Sofía, Vargas-Accarino, Elena, Gabriel-Medina, Pablo, Rodríguez-Frías, Francisco, Riveiro-Barciela, Mar, Perales, Celia, Quer, Josep, Sauleda, Silvia, Esteban Mur, Juan Ignacio, and Bes, Marta

Abstract

HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA's therapies

Published
2021

17. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study.

Author

Piratvisuth, Teerha, Tanwandee, Tawesak, Thongsawat, Satawat, Sukeepaisarnjaroen, Wattana, Esteban, Juan Ignacio, Bes, Marta, Köhler, Bruno, He, Ying, Swiatek‐de Lange, Magdalena, Morgenstern, David, and Chan, Henry Lik‐Yuen

Subjects
INSULIN-like growth factor-binding proteins, HEPATOCELLULAR carcinoma, CHRONIC hepatitis B, HEPATITIS B, EXTRACELLULAR matrix proteins, LENTILS, VITAMIN K
Abstract

Hepatocellular carcinoma (HCC), the sixth most common cancer worldwide, has an incidence rate equal to mortality. Over 80% of HCC cases occur within a high‐risk population, mainly patients with both cirrhosis and chronic hepatitis B or C. With a 5‐year survival rate ranging from <16% for advanced HCC to >90% for early stage HCC, there is a high medical need for the early detection of HCC. In this study, we systematically evaluated biomarkers mentioned in international guidelines and peer‐reviewed literature for HCC surveillance and diagnosis with the aim of identifying combinations that display high sensitivity and specificity for early stage HCC. Fifty biomarkers were measured in the first sample panel, panel A (n = 110), and subjected to univariate analysis. Of these, 35 biomarkers (38 assays) from panel A and an additional 13 biomarkers from the literature were prioritized for subsequent multivariate evaluation with lasso regression and exhaustive search of two‐ to four‐biomarker combinations (panel B). Panel B included 1,081 samples from patients with HCC (n = 308) or with chronic liver diseases (n = 740). Among all patients, 61.0% had hepatitis B, 32.9% had hepatitis C, and 60.5% had cirrhosis; 40.6% of patients with HCC had early stage cancer. Protein induced by vitamin K absence‐II (PIVKA‐II; also known as des‐gamma‐carboxy prothrombin [DCP]) and alpha‐fetoprotein (AFP) demonstrated the best clinical performance, both individually and in combination, and the addition of a third biomarker (Lens culinaris agglutinin‐reactive fraction of AFP [AFP‐L3], cartilage oligomeric matrix protein [COMP], insulin‐like growth factor‐binding protein 3 [IGFBP3], or matrix metalloproteinase 3 [MMP3]) further increased sensitivity for the detection of both early stage and all‐stage HCC. The addition of age and sex to the three‐biomarker panel resulted in an improved diagnostic performance. Conclusion: The combination of AFP and PIVKA‐II, with either IGFBP3, COMP or MMP3, plus age and sex, demonstrated the best performance for the detection of early‐ and all‐stage HCC. These novel panels performed similar to that of the GALAD score (sex [gender], age, plus serum levels of AFP, AFP‐L3 and DCP [PIVKA‐II]), a promising screening tool developed for HCC detection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Explorando los social media en la gestión de las relaciones con los clientes en empresas turísticas

Author

Domínguez Falcón, Carmen, Cerdán Bes, Marta, Domínguez Falcón, Carmen, and Cerdán Bes, Marta

Abstract

Managing customer relationships through collaborative digital environments has resulted in social CRM (SCRM). The SCRM emerges as a new business strategy that use 2.0 platforms. Doing so, organization will better manage their customers to be able to listen, meet and anticipate any need that may be required in order to maintain long-term relationships and loyalty. This research explores the importance of SCRM in companies linked to tourism in Gran Canaria (Canary Islands, Spain). For that, an exploratory investigation was carried out through in-depth interviews with executives of leading companies in this sector. The results indicate that SCRM is an issue of great interest and novelty, although scarcely implemented in a strategic and operational way among tourist companies. Knowing its impact on organizational performance is a challenge for research and for practice., La gestión de las relaciones con los clientes, a través del uso de entornos digitales colaborativos, ha dado lugar al CRM social (SCRM). El SCRM surge como una nueva estrategia de negocio que, a través del uso de plataformas 2.0, va a gestionar de forma más efectiva al cliente al ser capaz de escuchar, satisfacer e incluso anticiparse a cualquier necesidad que requiera, con el fin de mantener relaciones a largo plazo y fidelizarlo. Esta investigación explora la importancia del SCRM en empresas vinculadas al turismo en Gran Canaria (Islas Canarias, España). Para ello, se realizó una investigación exploratoria a través de entrevistas en profundidad a directivos de importantes empresas del sector. Los resultados señalan que se trata de un tema de gran interés y novedad, aunque escasamente implantado de forma estratégica y operativa entre las empresas turísticas. Conocer su impacto en los resultados organizativos supone un reto para la investigación y la práctica empresarial.

Published
2018

21. Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods

Author

Quer, Josep, primary, Gregori, Josep, additional, Rodríguez-Frias, Francisco, additional, Buti, Maria, additional, Madejon, Antonio, additional, Perez-del-Pulgar, Sofia, additional, Garcia-Cehic, Damir, additional, Casillas, Rosario, additional, Blasi, Maria, additional, Homs, Maria, additional, Tabernero, David, additional, Alvarez-Tejado, Miguel, additional, Muñoz, Jose Manuel, additional, Cubero, Maria, additional, Caballero, Andrea, additional, delCampo, Jose Antonio, additional, Domingo, Esteban, additional, Belmonte, Irene, additional, Nieto, Leonardo, additional, Lens, Sabela, additional, Muñoz-de-Rueda, Paloma, additional, Sanz-Cameno, Paloma, additional, Sauleda, Silvia, additional, Bes, Marta, additional, Gomez, Jordi, additional, Briones, Carlos, additional, Perales, Celia, additional, Sheldon, Julie, additional, Castells, Lluis, additional, Viladomiu, Lluis, additional, Salmeron, Javier, additional, Ruiz-Extremera, Angela, additional, Quiles-Pérez, Rosa, additional, Moreno-Otero, Ricardo, additional, López-Rodríguez, Rosario, additional, Allende, Helena, additional, Romero-Gómez, Manuel, additional, Guardia, Jaume, additional, Esteban, Rafael, additional, Garcia-Samaniego, Javier, additional, Forns, Xavier, additional, and Esteban, Juan Ignacio, additional

Published
2016
Full Text
View/download PDF

22. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods

Author

Centro para el Desarrollo Tecnológico Industrial (España), Ministerio de Economía y Competitividad (España), Ministerio de Sanidad y Consumo (España), Fundación para la Investigación y la Prevención del Sida en España, Fundación Ramón Areces, Instituto de Salud Carlos III, Quer, Josep, Domingo, Esteban, Saudela, Silvia, Bes, Marta, Perales, Celia, Sheldon, Julie, Esteban, Juan Ignacio, Centro para el Desarrollo Tecnológico Industrial (España), Ministerio de Economía y Competitividad (España), Ministerio de Sanidad y Consumo (España), Fundación para la Investigación y la Prevención del Sida en España, Fundación Ramón Areces, Instituto de Salud Carlos III, Quer, Josep, Domingo, Esteban, Saudela, Silvia, Bes, Marta, Perales, Celia, Sheldon, Julie, and Esteban, Juan Ignacio

Abstract

All Rights Reserved. HepatitisCvirus(HCV)is classified into seven major genotypesand67 subtypes. Recent studies haveshownthat inHCVgenotype 1-infected patients, response rates to regimens containingdirect-acting antivirals(DAAs)are subtype dependent. Currently available genotypingmethods have limited subtyping accuracy.Wehave evaluated theperformanceof adeep-sequencing-basedHCVsubtyping assay, developed for the 454/GS-Junior platform, in comparisonwith thoseof two commercial assays (VersantHCVgenotype 2.0andAbbott Real-timeHCVGenotype II)andusingdirectNS5Bsequencing as a gold standard (direct sequencing), in 114 clinical specimenspreviously tested by first-generation hybridization assay (82 genotype 1and32 with uninterpretable results). Phylogenetic analysis of deep-sequencing reads matched subtype 1 callingbypopulation Sanger sequencing(69%1b,31%1a) in 81 specimensandidentified amixed-subtype infection (1b/3a/1a) in one sample. Similarly,amongthe 32previously indeterminate specimens, identical genotypeandsubtype results were obtained by directanddeep sequencing in all but four samples with dual infection. In contrast, both VersantHCVGenotype 2.0andAbbott Real-timeHCVGenotype II failed subtype 1 calling in 13 (16%) samples eachandwere unable to identify theHCVgenotype and/or subtype inmore than half of the nongenotype 1 samples.Weconcluded that deep sequencing ismore efficient forHCVsubtyping than currently available methodsandallows qualitative identificationofmixed infectionsandmay bemorehelpfulwith respect to informing treatment strategies withnewDAA-containing regimens across allHCVsubtypes.

Published
2015

23. High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods

Author

Quer, Josep, primary, Gregori, Josep, additional, Rodríguez-Frias, Francisco, additional, Buti, Maria, additional, Madejon, Antonio, additional, Perez-del-Pulgar, Sofia, additional, Garcia-Cehic, Damir, additional, Casillas, Rosario, additional, Blasi, Maria, additional, Homs, Maria, additional, Tabernero, David, additional, Alvarez-Tejado, Miguel, additional, Muñoz, Jose Manuel, additional, Cubero, Maria, additional, Caballero, Andrea, additional, delCampo, Jose Antonio, additional, Domingo, Esteban, additional, Belmonte, Irene, additional, Nieto, Leonardo, additional, Lens, Sabela, additional, Muñoz-de-Rueda, Paloma, additional, Sanz-Cameno, Paloma, additional, Sauleda, Silvia, additional, Bes, Marta, additional, Gomez, Jordi, additional, Briones, Carlos, additional, Perales, Celia, additional, Sheldon, Julie, additional, Castells, Lluis, additional, Viladomiu, Lluis, additional, Salmeron, Javier, additional, Ruiz-Extremera, Angela, additional, Quiles-Pérez, Rosa, additional, Moreno-Otero, Ricardo, additional, López-Rodríguez, Rosario, additional, Allende, Helena, additional, Romero-Gómez, Manuel, additional, Guardia, Jaume, additional, Esteban, Rafael, additional, Garcia-Samaniego, Javier, additional, Forns, Xavier, additional, and Esteban, Juan Ignacio, additional

Published
2015
Full Text
View/download PDF

25. High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods

Author

Quer, Josep, Gregori, Josep, Rodríguez-Frias, Francisco, Buti, Maria, Madejon, Antonio, Perez-del-Pulgar, Sofia, Garcia-Cehic, Damir, Casillas, Rosario, Blasi, Maria, Homs, Maria, Tabernero, David, Alvarez-Tejado, Miguel, Muñoz, Jose Manuel, Cubero, Maria, Caballero, Andrea, delCampo, Jose Antonio, Domingo, Esteban, Belmonte, Irene, Nieto, Leonardo, Lens, Sabela, Muñoz-de-Rueda, Paloma, Sanz-Cameno, Paloma, Sauleda, Silvia, Bes, Marta, Gomez, Jordi, Briones, Carlos, Perales, Celia, Sheldon, Julie, Castells, Lluis, Viladomiu, Lluis, Salmeron, Javier, Ruiz-Extremera, Angela, Quiles-Pérez, Rosa, Moreno-Otero, Ricardo, López-Rodríguez, Rosario, Allende, Helena, Romero-Gómez, Manuel, Guardia, Jaume, Esteban, Rafael, Garcia-Samaniego, Javier, Forns, Xavier, and Esteban, Juan Ignacio

Abstract

ABSTRACTHepatitis C virus (HCV) is classified into seven major genotypes and 67 subtypes. Recent studies have shown that in HCV genotype 1-infected patients, response rates to regimens containing direct-acting antivirals (DAAs) are subtype dependent. Currently available genotyping methods have limited subtyping accuracy. We have evaluated the performance of a deep-sequencing-based HCV subtyping assay, developed for the 454/GS-Junior platform, in comparison with those of two commercial assays (Versant HCV genotype 2.0 and Abbott Real-time HCV Genotype II) and using direct NS5B sequencing as a gold standard (direct sequencing), in 114 clinical specimens previously tested by first-generation hybridization assay (82 genotype 1 and 32 with uninterpretable results). Phylogenetic analysis of deep-sequencing reads matched subtype 1 calling by population Sanger sequencing (69% 1b, 31% 1a) in 81 specimens and identified a mixed-subtype infection (1b/3a/1a) in one sample. Similarly, among the 32 previously indeterminate specimens, identical genotype and subtype results were obtained by direct and deep sequencing in all but four samples with dual infection. In contrast, both Versant HCV Genotype 2.0 and Abbott Real-time HCV Genotype II failed subtype 1 calling in 13 (16%) samples each and were unable to identify the HCV genotype and/or subtype in more than half of the non-genotype 1 samples. We concluded that deep sequencing is more efficient for HCV subtyping than currently available methods and allows qualitative identification of mixed infections and may be more helpful with respect to informing treatment strategies with new DAA-containing regimens across all HCV subtypes.

Published
2014
Full Text
View/download PDF

26. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience.

Author

Piron M, Salvador F, Caballero E, Sánchez-Montalvá A, Bes M, Casamitjana N, Puig L, Molina I, and Sauleda S

Subjects
Adult, Deltaretrovirus, Female, Human T-lymphotropic virus 2, Humans, Male, Spain epidemiology, Blood Donors, HTLV-I Infections diagnosis, HTLV-I Infections epidemiology, HTLV-II Infections diagnosis, HTLV-II Infections epidemiology, Human T-lymphotropic virus 1 genetics
Abstract

Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d'Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety., Competing Interests: The authors declare no conflict of interest.

Published
2022
Full Text
View/download PDF

27. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain).

Author

Piron M, Jané M, Ciruela P, Basile L, Martínez A, Puig L, Bes M, and Sauleda S

Subjects
Antibodies, Viral, Blood Donors, Communicable Disease Control, Humans, Immunoglobulin G, Immunoglobulin M, Pandemics, Prospective Studies, Retrospective Studies, Seroepidemiologic Studies, Spain epidemiology, COVID-19 epidemiology, SARS-CoV-2
Abstract

Background: Due to the COVID-19 pandemic, a national lockdown was applied in Spain from March to May 2020. It is uncertain when SARS-CoV-2 started to circulate in Catalonia, and only a few cases were diagnosed in this period. We assessed the SARS-CoV-2 seroprevalence in blood donors before and after the first wave and compared it with public health service (PHS) data., Materials and Methods: Retrospective archive or prospective fresh blood samples were obtained from blood donors aged 18 to 70 and anonymized after demographic data had been recorded (gender, age, place of residence, blood collection date). Two CE-marked enzyme-linked immunosorbent assays were used to test for anti-SARS-CoV-2. A SARS-CoV-2 IgM test was additionally performed in positive samples. Individuals aged 18 to 70 from among the general population diagnosed as having SARS-CoV-2 by the PHS were included for comparison with blood donor results., Results: A total of 10,170 blood donations were included in the first period, between 24 February and 9 March 2020, and 6,829 in the second period, between 16 May and 17 June 2020. The observed SARS-CoV-2 seroprevalence among blood donors rose from 0.27% (95% CI: 0.18-0.39) before the first wave to 5.55% (95% CI: 5.03-6.12) after it, and was even higher (6.90% [95% CI: 5.64-8.41]) among blood donors aged 18 to 29. The seroprevalence among blood donors was higher in more populated areas (Barcelona: 7.69%). A comparison of blood donor data with officially diagnosed cases showed a global 87.44% underestimation of SARS-CoV-2 in June 2020., Discussion: We analyzed the explosive 3-month increase in blood donor SARS-CoV-2 seroprevalence (from 0.27% to 5.55%) and show that more than 87% of cases went undiagnosed, despite the unprecedented deployment of testing measures. SARS-CoV-2 IgM results suggest that the virus was circulating among blood donors in February 2020. Blood donors are definitively proven to be a valuable resource for emerging disease surveillance studies.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results